Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients

References

• Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9(Suppl 3):S1–155.
   PubMed Web of Science ®Google Scholar
• Hart A, Lentine KL, Smith JM, et al. OPTN/SRTR 2019 annual data report: kidney. Am J Transplant. 2021 Feb;21(Suppl 2):21–137.
   PubMedGoogle Scholar
• Prograf® prescribing information. Northbrook (IL): Astellas Pharm US, Inc; 2018.
   Google Scholar
• Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623–653.
   PubMed Web of Science ®Google Scholar
• Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharmacol Ther. 2015 Jul;98(1):19–24.
   PubMed Web of Science ®Google Scholar
• Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy. 2021 Jan;41(1):103–118.
   PubMed Web of Science ®Google Scholar
• Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplant Rev (Orlando). 2015 Apr;29(2):78–84.
   PubMedGoogle Scholar
• Bunnapradist S, Ciechanowski K, West-Thielke P, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Am J Transplant. 2013;13(3):760–769.
   PubMed Web of Science ®Google Scholar
• Budde K, Bunnapradist S, Grinyo JM, et al. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Am J Transplant. 2014 Dec;14(12):2796–2806.
   PubMed Web of Science ®Google Scholar
• Rostaing L, Bunnapradist S, Grinyó JM, et al. Novel once-daily extended-release tacrolimus versus twice-daily tacrolimus in De Novo kidney transplant recipients: two-year results of phase 3, double-blind, randomized trial. Am J Kidney Dis. 2016 Apr;67(4):648–659.
   PubMed Web of Science ®Google Scholar
• Nigro V, Glicklich A, Weinberg J. Improved bioavailability of MELTDOSE once-daily formulation of tacrolimus (LCP-Tacro) with controlled agglomeration allows for consistent absorption over 24 Hrs: a scintigraphic and pharmacokinetic evaluation [abstract]. Am J Transplant. 2013;13(suppl 5).
   Google Scholar
• Gelder TV, Etsouli O, Moes DJ, et al. Comparison of the impact of pharmacogenetic variability on the PK of slow release and immediate release tacrolimus formulations. Genes (Basel). 2020 Oct 15;11(10):1205.
   Web of Science ®Google Scholar
• Envarsus XR® (tacrolimus extended-release tablets), prescribing information. Cary (NC): Veloxis Pharmaceuticals, Inc; 2018.
   Google Scholar
• Envarsus EPAR prescribing information. Parma (IT): Chiesi Farmaceutici S.p.A.; 2019.
   Google Scholar
• Envarsus® PA tacrolimus prolonged-release tablets, prescribing information. Saint-Laurent (QC): Paladin Labs Inc; 2020.
   Google Scholar
• Gaber AO, Alloway RR, Bodziak K, et al. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation. 2013 Jul 27;96(2):191–197.
   PubMed Web of Science ®Google Scholar
• Tremblay S, Nigro V, Weinberg J, et al. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017 Feb;17(2):432–442.
   PubMed Web of Science ®Google Scholar
• Tremblay S, Alloway RR. Clinical evaluation of modified release and immediate release tacrolimus formulations. AAPS J. 2017 Sep;19(5):1332–1347.
   PubMed Web of Science ®Google Scholar
• Langone A, Steinberg SM, Gedaly R, et al. Switching study of kidney transplant patients with tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015 Sep;29(9):796–805.
   PubMed Web of Science ®Google Scholar
• Thölking G, Fortmann C, Koch R, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS One. 2014 Oct 23;9(10):e111128.
   PubMed Web of Science ®Google Scholar
• Oberbauer R, Bestard O, Furian L, et al. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives. Transplant Rev (Orlando). 2020 Apr;34(2):100531.
   PubMedGoogle Scholar
• Suwelack B, Bunnapradist S, Meier-Kriesche U, et al. Effect of concentration/dose ratio in de novo kidney transplant recipients receiving LCP-tacrolimus or immediate-release tacrolimus: post hoc analysis of a phase 3 clinical trial. Ann Transplant. 2020 Jul 28;25:e923278.
   PubMed Web of Science ®Google Scholar
• Sánchez Fructuoso A, Ruiz JC, Franco A, et al. Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study. Clin Transplant. 2020 Jan;34(1):e13767.
   PubMed Web of Science ®Google Scholar
• Franco A, Más-Serrano P, Balibrea N, et al. Envarsus, a novelty for transplant nephrologists: observational retrospective study. Nefrologia (Engl Ed). 2019 Sep-Oct;39(5):506–512.
   PubMedGoogle Scholar
• Trofe-Clark J, Brennan DC, West-Thielke P, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis. 2018 Mar;71(3):315–326.
   PubMed Web of Science ®Google Scholar
• Jacobson PA. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011 Feb 15;91(3):300–308.
   PubMed Web of Science ®Google Scholar
• Oetting WS, Schladt DP, Guan W, et al. Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles. Am J Transplant. 2016 Feb;16(2):574–582.
   PubMed Web of Science ®Google Scholar
• Bunnapradist S, Rostaing L, Alloway RR, et al. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Transpl Int. 2016 May;29(5):603–611.
   PubMed Web of Science ®Google Scholar
• Faravardeh A, Akkina S, Villicana R, et al. Efficacy and safety of once-daily LCP-tacrolimus versus twice-daily immediate-release tacrolimus in adult Hispanic stable kidney transplant recipients: sub-group analysis from a phase 3 trial. Ann Transplant. 2021 Apr 16;26:e929535.
   PubMed Web of Science ®Google Scholar
• Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012 Dec;12(12):3326–3336.
   PubMed Web of Science ®Google Scholar
• January SE, Hagopian JC, Nesselhauf NM, et al. Clinical experience with extended-release tacrolimus in older adult kidney transplant recipients: a retrospective cohort study. Drugs Aging. 2021 May;38(5):397–406.
   PubMed Web of Science ®Google Scholar
• Huppertz A, Ott C, Bruckner T, et al. Prolonged-release tacrolimus is less susceptible to interaction with the strong CYP3A inhibitor voriconazole in healthy volunteers. Clin Pharmacol Ther. 2019 Dec;106(6):1290–1298.
   PubMed Web of Science ®Google Scholar
• Lange NW, Hedvat J, Tsapepas DS, et al. Managing the significant interaction between XR tacrolimus and fluconazole in kidney transplant recipients. Clin Transplant. 2020 Aug;34(8):e14001.
   PubMed Web of Science ®Google Scholar
• Hedvat J, Choe JY, Salerno DM, et al. Managing the significant drug-drug interaction between tacrolimus and letermovir in solid organ transplant recipients. Clin Transplant. 2021 Mar;35(3):e14213.
   PubMed Web of Science ®Google Scholar
• Harkness TM, Cohen EA, Asch WS, et al. Clinical implications of unique drug interaction between extended release tacrolimus and phenytoin. Prog Transplant. 2020 Jun;30(2):177–178.
   PubMed Web of Science ®Google Scholar
• Alloway RR, Trofe-Clark J, Brennan DC, et al. Chronopharmacokinetics and food effects of single-dose LCP-tacrolimus in healthy volunteers. Ther Drug Monit. 2020 Oct;42(5):679–685.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine. [2021; cited 2021 Apr 28]. Available from: http://clinicaltrials.gov.
   Google Scholar